- Sankyo is to codevelop and comarket a highly-selective alpha1 receptor antagonist, developed by Italian firm Recordati for the treatment of benign prostatic hypertrophy, in Japan. Recordati is currently testing the drug, called REC 15-2739, in Phase II trials in the USA and UK. The cross-licensing agreement also gives Recordati rights to codevelop and comarket CS-866, an angiotensin II receptor antagonist developed by Sankyo for the treatment of hypertension, in Spain and Italy. This compound is completing Phase I studies in Europe, Japan and the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze